Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
about
Progeria: a rare genetic premature ageing disorderThe FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular PhenotypeHow Research on Human Progeroid and Antigeroid Syndromes Can Contribute to the Longevity Dividend InitiativeDrug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation.Tipifarnib prevents development of hypoxia-induced pulmonary hypertension.Metformin decreases progerin expression and alleviates pathological defects of Hutchinson-Gilford progeria syndrome cells.DNA repair defects and genome instability in Hutchinson-Gilford Progeria Syndrome.Preventing farnesylation of the dynein adaptor Spindly contributes to the mitotic defects caused by farnesyltransferase inhibitors.Nesprin-2G, a Component of the Nuclear LINC Complex, Is Subject to Myosin-Dependent Tension.Modulation of LMNA splicing as a strategy to treat prelamin A diseases.Prelamin A processing, accumulation and distribution in normal cells and laminopathy disorders.Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria SyndromeCardiac electrical defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations.Comparing lamin proteins post-translational relative stability using a 2A peptide-based system reveals elevated resistance of progerin to cellular degradation.A novel somatic mutation achieves partial rescue in a child with Hutchinson-Gilford progeria syndrome.Nuclear lamina remodelling and its implications for human disease.Hutchinson-Gilford Progeria Syndrome: A Premature Aging Disease.Speeding up the clock: The past, present and future of progeria.The nuclear lamina in health and disease.Hutchinson-Gilford Progeria Syndrome: A premature aging disease caused by LMNA gene mutations.Arterial Calcification in Diabetes Mellitus: Preclinical Models and Translational Implications.Exploring the biochemistry of the prenylome and its role in disease through proteomics: progress and potential.Progerin impairs chromosome maintenance by depleting CENP-F from metaphase kinetochores in Hutchinson-Gilford progeria fibroblasts.Vitamin D receptor signaling improves Hutchinson-Gilford progeria syndrome cellular phenotypes.MG132-induced progerin clearance is mediated by autophagy activation and splicing regulation.Vascular Aging: Implications for Cardiovascular Disease and Therapy.Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts.Seeking a Cure for One of the Rarest Diseases: Progeria.The decision-making process and criteria in selecting candidate drugs for progeria clinical trials.An encouraging progress report on the treatment of progeria and its implications for atherogenesis.Metformin alleviates ageing cellular phenotypes in Hutchinson-Gilford progeria syndrome dermal fibroblasts.Heart rate reduction and longevity in mice.Computational Exploration for Lead Compounds That Can Reverse the Nuclear Morphology in Progeria.Protein Lipidation: Occurrence, Mechanisms, Biological Functions, and Enabling Technologies.Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome.Shared molecular and cellular mechanisms of premature ageing and ageing-associated diseases.Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice.The clinical characteristics of Asian patients with classical-type Hutchinson-Gilford progeria syndrome.Vascular Smooth Muscle-Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome.
P2860
Q24564144-460BB3B0-0420-494B-BB7B-EB59F652F016Q27853172-9806B127-C2D8-4F1D-BDC7-2D0776C7DF2AQ28468499-3A418484-77D0-43C0-8C6A-6C7DA8645F71Q28601451-00CEC872-58D2-4DE6-8ADB-EB2ACBCCA9D4Q30846580-98205BD9-5E7F-450B-A350-40538B22E466Q33614140-72AA4FF8-8008-4875-B593-C6E88ED6DBD9Q33914338-CD61B373-3FDB-4539-B4FD-FE3A5EE21D96Q34480944-06C57807-EFD7-47D7-87D4-0981EB55380CQ35621957-231D292B-4E28-477A-A024-F682B0116176Q36724244-63A8E409-9096-4B73-8FB7-D83617290094Q36737860-08CBE639-5DE7-47D3-AB50-7A01B1F917CCQ37028510-87FBAB93-4251-4251-BE9F-B898856A919CQ37091901-7FCA02AB-0A25-4F43-AB27-D5F527247332Q37469701-3C1F02BD-A946-4458-BAC8-E8B24A01FA8CQ37558746-10B807E2-C913-436B-8476-22B4F48D9B2AQ37741619-364011A7-095D-4340-92EC-872A2C231D4DQ38297406-44B77FC1-0AE7-41D3-BE21-B1C37A78B6D1Q38665343-EFA90027-F3F8-4AF0-B2E4-48D1C7EFE91CQ38675558-1BE2DDA1-5E84-4BCA-8CB6-C795085F045AQ38829530-A0FCC3F1-0A44-4FCB-9465-271EFE986569Q38885070-41C26549-95D1-49BF-8760-B43E4832A071Q39071314-014ECE4F-9FC1-475B-9042-5E4BD9DFD233Q39316007-90A5999F-2F66-4B9A-8880-D9AE7D7685ADQ41134538-BD9C982B-9AF2-4BB1-B1AC-1B834F435A6DQ41416839-74B0B3CA-86D6-4CA2-9215-91463B760E1DQ41601030-87E58CEF-02BF-434B-B7E3-B3CA4BFF74DCQ41728173-19E7E89C-F24B-4D37-9D2C-64374CB58106Q42371472-4639B6B9-7E38-4974-8D98-30981B492E2DQ42371479-728F51FD-B5A2-4611-930B-F29A809747CEQ42434438-415771AC-EE97-450C-9D21-E2911FDBF733Q43140936-9E519EB3-300E-4878-9F47-F9D7BCF92B27Q46418627-52DDD6D8-A70E-45EB-85A4-C15A8602AB0AQ46786545-AE1698FF-F7C4-4268-8B15-10ECE3133FD1Q46902686-9E695776-501F-4ACA-B803-7B92812EE911Q47239374-D43376D4-826F-4806-876D-4F7284F10F2FQ47414799-4CEB271D-819C-4065-A98D-FCC8641D2DDDQ47974120-10591A77-3236-45A0-BFB7-9DE036DEADAEQ50054188-032367AC-6AB6-42BC-B9D0-36258CAD98CCQ50212283-2DB1CB65-905A-4C7A-8B5C-C15A005ECFD0Q51766620-A2C6E8F9-C33B-479B-BF77-891FFEC79C65
P2860
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
@ast
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
@en
type
label
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
@ast
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
@en
prefLabel
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
@ast
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
@en
P2093
P2860
P1433
P1476
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome
@en
P2093
Joan Brazier
Joe Massaro
Leslie B Gordon
Monica E Kleinman
Progeria Clinical Trials Collaborative
Ralph B D'Agostino
Susan E Campbell
W Ted Brown
P2860
P356
10.1161/CIRCULATIONAHA.113.008285
P407
P577
2014-05-02T00:00:00Z